UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

 

Commission File Number  

001-36575

 

MACROCURE LTD.

(Exact name of registrant as specified in its charter)

 

c/o Leap Therapeutics, Inc.

47 Thorndike Street

Suite B1-1

(617) 714-0360

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

Ordinary Shares, par value NIS 0.01 per share

(Title of each class of securities covered by this Form)

 

None.

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

 

Rule 12g-4(a)(1)

x

 

 

 

 

 

Rule 12g-4(a)(2)

o

 

 

 

 

 

Rule 12h-3(b)(1)(i)

x

 

 

 

 

 

Rule 12h-3(b)(1)(ii)

o

 

 

 

 

 

Rule 15d-6

o

 

 

 

 

 

Rule 15d-22(b)

o

 

 

 

 

 

Approximate number of holders of record as of the certification or notice date: 1

 

Pursuant to the requirements of the Securities Exchange Act of 1934 Macrocure Ltd. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date:

02/06/2017

 

By:

/s/ Douglas Onsi

 

 

 

 

 

Douglas Onsi

 

 

 

 

 

Director

 

 


 

Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Leap Therapeutics Charts.
Leap Therapeutics (NASDAQ:LPTX)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Leap Therapeutics Charts.